Crispr Genomic Cure Market to Grow with a CAGR of 29.21% through 2028
Increased
investment and expanding applications are expected to drive the Global Crispr
Genomic Cure Market growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Crispr Genomic Cure Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2028”, the
Global Crispr Genomic Cure Market stood at USD 1.89 billion in 2022 and is
anticipated to grow with a CAGR of 29.21% in the forecast period, 2024-2028.
This can be attributed to public awareness and acceptance. As the public
becomes more aware of the potential of CRISPR technology, there is greater
acceptance of its use in medicine. This acceptance contributes to increased patient
enrollment in clinical trials and fosters a supportive environment for market
growth.
Furthermore,
with the expansion of CRISPR applications, there is an increased focus on
establishing robust ethical and regulatory frameworks. Governments and
regulatory agencies are working to develop guidelines that balance innovation
with safety and ethics. Compliance with these frameworks will be crucial for
market growth.
CRISPR
technology represents a distinctive tool for precise gene editing and
regulation, adaptable to a variety of biological systems. Scientists utilize
CRISPR to modify genes within plant, bacterial, and animal models,
significantly advancing our comprehension of the genetic underpinnings of
diseases and facilitating the development of improved therapeutics. This
innovation enables the efficient and cost-effective creation of disease models
through precise genome editing, accurately replicating the disease in question.
Furthermore, it
has found utility as an experimental assay for detecting novel coronaviruses.
CRISPR, as a gene-editing technology, stands poised to reshape our world. The
increasing prevalence of chronic, genetic, infectious, neurological, blood, and
metabolic diseases, along with a growing elderly population, heightened demand
for safe and effective treatments, augmented funding for cell and gene
therapies, consistent approvals for gene therapies, the introduction of novel
treatments, and growing public awareness of CRISPR genomic cures are pivotal
factors expected to fuel the global CRISPR genomic cure market's growth in the
foreseeable future.
For example, in
March 2021, researchers from UC San Francisco, UC Berkeley, and UCLA received
FDA approval to collaboratively initiate a first-in-human clinical trial for a
CRISPR-based gene correction therapy aimed at sickle cell disease patients,
using their own blood-forming stem cells. This therapy has the potential to
revolutionize sickle cell disease treatment, offering a safer and more
accessible curative option compared to the current procedure involving stem
cell transplants from healthy bone marrow donors, and potentially averting
irreversible disease-related complications.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global Crispr Genomic Cure Market”
The Global
Crispr Genomic Cure Market is segmented into disease type, therapy type,
delivery method, end user, targeted genetic modification, regional
distribution, and company.
Based on its
disease type, Genetic disorders are poised to dominate the global CRISPR
genomic cure market in 2022 due to several compelling factors. Firstly, the
prevalence of genetic disorders worldwide is alarmingly high, affecting
millions of individuals and their families. This widespread demand for
effective treatments has spurred intense research and development efforts
within the biotechnology and pharmaceutical industries, with CRISPR-based
therapies emerging as a promising solution. Additionally, the versatility and
precision of CRISPR technology make it a frontrunner in the race to address
genetic disorders, allowing for targeted modifications and corrections of
faulty genes. Furthermore, the growing awareness of CRISPR's potential to
revolutionize healthcare, coupled with advancements in regulatory frameworks,
investment influx, and international collaborations, is creating a conducive
environment for the expansion of the CRISPR genomic cure market. As the
understanding of genetics deepens and CRISPR-based therapies continue to prove
their efficacy, the dominance of genetic disorder treatments in this market is
not only foreseeable but also a significant driver of innovation and growth in
the life sciences sector.
Based on region,
North America is poised to dominate the global CRISPR genomic cure market in
2022 for several compelling reasons. Firstly, the region boasts a robust
ecosystem of biotechnology and pharmaceutical companies, many of which are
pioneers in CRISPR technology research and development. These companies have
access to substantial resources, attracting top talent and fostering innovation
in the field. Additionally, North America benefits from a well-established
regulatory framework that, while stringent, provides a clear path for the
approval and commercialization of CRISPR-based therapies, ensuring their rapid
adoption. Furthermore, the region's strong emphasis on healthcare
infrastructure, research institutions, and academic collaborations enhances the
development and application of CRISPR technology. Lastly, a large patient
population and high healthcare expenditure levels in North America create a
significant market demand for innovative treatments, making it an attractive
destination for CRISPR genomic cures. Collectively, these factors position
North America at the forefront of the global CRISPR genomic cure market,
driving innovation, accessibility, and market leadership in this transformative
field of medicine.
Major companies
operating in Global Crispr Genomic Cure Market are:
- Merck KGaA
- Takara Bio Inc
- Lonza Group AG
- Horizon Discovery Group Ltd
- Genscript Biotech Corp
- Synthego Corp
- Precision BioSciences Inc
- Mammoth Biosciences Inc
- Thermo Fisher Scientific Inc
- Intellia Therapeutics Inc
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The global
CRISPR genomic cure market is on the cusp of transformative growth. From
expanding therapeutic applications to precision medicine and advanced delivery
methods, the future of CRISPR technology promises innovative solutions for a
wide range of diseases. However, it is essential to navigate the ethical,
regulatory, and societal considerations that accompany these advancements to
ensure responsible and equitable progress in the CRISPR genomic cure market. As
these trends continue to unfold, they hold the potential to redefine the
landscape of healthcare and biotechnology,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Crispr Genomic Cure Market By Disease Type
(Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders,
Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others), By
Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy), By
Delivery Method (In vivo, Ex vivo), By End User (Hospitals & Clinics,
Research Institutes, Biotechnology & Pharmaceutical Companies), By Targeted
Genetic Modification (Single Gene Modification, Multiple Gene Modification,
Genome-wide Modification), By
Region, By Competition Forecast
& Opportunities, 2018-2028F”, has evaluated the future growth
potential of Global Crispr Genomic Cure Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Crispr Genomic Cure Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com